Literature DB >> 2853610

CA19-9, CA125 and CEA in endometrial carcinoma tissue and its relation to hormone receptor content and histological grading.

W Neunteufel1, C Bieglmayer, G Breitenecker.   

Abstract

Samples of 40 endometrial carcinomas were examined by immunohistochemical methods for CA19-9, CA125 and CEA. CA19-9 was detected in 93%, CA125 in 65% and CEA in 58%. CA19-9 was detected in more than 50% of tumor cells in 14 cases and the same was true for CA125 in six cases. In no tumor was CEA found in more than half the cells. The distribution of CA125 and CEA was markedly more heterogenous than that of CA19-9. There was no statistically significant correlation between immunohistochemical markers on the one hand, and estrogen and progesterone receptor content on the other. A correlation between histological grading and marker detection was only found for CA19-9. CA19-9 was detected in almost all endometrial carcinoma samples, and was the most homogenously distributed. This makes CA19-9 a possibly useful tumor marker for endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2853610     DOI: 10.1007/bf00931402

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  16 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Tumour markers in ovarian cancer.

Authors:  J R van Nagell
Journal:  Clin Obstet Gynaecol       Date:  1983-08

3.  Significance of serum tumor markers in patients with carcinoma of the ovary.

Authors:  Y Kikuchi; I Kizawa; E Koyama; K Kato
Journal:  Obstet Gynecol       Date:  1984-04       Impact factor: 7.661

4.  Carcinoembryonic antigen (CEA) and carbohydrate determinant 19-9 (CA 19-9) localization in 121 primary and metastatic ovarian tumors: an immunohistochemical study with the use of monoclonal antibodies.

Authors:  C Charpin; A K Bhan; V R Zurawski; R E Scully
Journal:  Int J Gynecol Pathol       Date:  1982       Impact factor: 2.762

5.  CA 125: a useful marker in endometrial carcinoma.

Authors:  J M Duk; J G Aalders; G J Fleuren; H W de Bruijn
Journal:  Am J Obstet Gynecol       Date:  1986-11       Impact factor: 8.661

6.  Immunohistochemical demonstration of several tumour markers in neoplastic and preneoplastic states of the uterine mucosa.

Authors:  J Hustin
Journal:  Gynecol Obstet Invest       Date:  1978       Impact factor: 2.031

7.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

8.  Simultaneous inhibition of endogenous avidin-binding activity and peroxidase applicable for the avidin-biotin system using monoclonal antibodies.

Authors:  Y Matsumoto
Journal:  Histochemistry       Date:  1985

9.  Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.

Authors:  H M Davis; V R Zurawski; R C Bast; T L Klug
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

10.  Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.

Authors:  R C Bast; T L Klug; E Schaetzl; P Lavin; J M Niloff; T F Greber; V R Zurawski; R C Knapp
Journal:  Am J Obstet Gynecol       Date:  1984-07-01       Impact factor: 8.661

View more
  3 in total

1.  Type-1 chain histo-blood group antigens (Le(a), monosialosyl-Le(a), disialosyl-Le(a), Le(b), and H) in normal and malignant human endometrium.

Authors:  V Ravn; U Mandel; B Svenstrup; E Dabelsteen
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

2.  Serum carcinoembryonic antigen as a tumour marker in patients with endometrial cancer.

Authors:  Y Hashiguchi; M Kasai; T Fukuda; T Ichimura; T Yasui; T Sumi
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

3.  CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding.

Authors:  Kumar U Nithin; M G Sridhar; K Srilatha; S Habebullah
Journal:  Afr Health Sci       Date:  2018-12       Impact factor: 0.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.